AU2005250142B2 - Biomarkers for the prediction of responsiveness to clozapine treatment - Google Patents

Biomarkers for the prediction of responsiveness to clozapine treatment Download PDF

Info

Publication number
AU2005250142B2
AU2005250142B2 AU2005250142A AU2005250142A AU2005250142B2 AU 2005250142 B2 AU2005250142 B2 AU 2005250142B2 AU 2005250142 A AU2005250142 A AU 2005250142A AU 2005250142 A AU2005250142 A AU 2005250142A AU 2005250142 B2 AU2005250142 B2 AU 2005250142B2
Authority
AU
Australia
Prior art keywords
patient
slc6a3
gene
polymorphism
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005250142A
Other languages
English (en)
Other versions
AU2005250142A1 (en
Inventor
Yunsheng He
Elisabeth Marie Leroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2005250142A1 publication Critical patent/AU2005250142A1/en
Application granted granted Critical
Publication of AU2005250142B2 publication Critical patent/AU2005250142B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005250142A 2004-06-04 2005-06-03 Biomarkers for the prediction of responsiveness to clozapine treatment Ceased AU2005250142B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57713104P 2004-06-04 2004-06-04
US60/577,131 2004-06-04
PCT/EP2005/006002 WO2005118848A1 (en) 2004-06-04 2005-06-03 Biomarkers for the prediction of responsiveness to clozapine treatment

Publications (2)

Publication Number Publication Date
AU2005250142A1 AU2005250142A1 (en) 2005-12-15
AU2005250142B2 true AU2005250142B2 (en) 2008-08-21

Family

ID=34970966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005250142A Ceased AU2005250142B2 (en) 2004-06-04 2005-06-03 Biomarkers for the prediction of responsiveness to clozapine treatment

Country Status (10)

Country Link
US (1) US20090281090A1 (enExample)
EP (1) EP1756314A1 (enExample)
JP (1) JP2008505060A (enExample)
CN (1) CN1973051A (enExample)
AU (1) AU2005250142B2 (enExample)
BR (1) BRPI0510775A (enExample)
CA (1) CA2568729A1 (enExample)
MX (1) MXPA06014127A (enExample)
RU (1) RU2006146207A (enExample)
WO (1) WO2005118848A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136996A2 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting ace-related disorders and uses thereof
US7932042B1 (en) 2010-10-13 2011-04-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
US20130029862A1 (en) * 2011-06-02 2013-01-31 Gareth Davies Clinical application utilizing genetic data for effective medication management
EP2883052B8 (en) 2012-08-10 2019-03-13 Istituto Superiore di Sanità Biomarkers
CN112195230B (zh) * 2020-09-17 2022-08-23 青岛大学附属医院 一种用于氯氮平个体化用药指导的基因检测试剂、试剂盒、检测方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381525A (en) * 2001-11-01 2003-05-07 Tcs Cellworks Ltd Regulating gene expression
AU2004213582A1 (en) * 2003-02-21 2004-09-02 Novartis Ag Methods for the prediction of suicidality during treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207989A1 (en) * 2002-02-21 2003-09-09 Idgene Pharmaceuticals Ltd. Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
WO2003101377A2 (en) * 2002-06-03 2003-12-11 Idgene Pharmaceuticals Ltd. Association of snps in the dgcr2 locus and neighboring loci with schizophrenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381525A (en) * 2001-11-01 2003-05-07 Tcs Cellworks Ltd Regulating gene expression
AU2004213582A1 (en) * 2003-02-21 2004-09-02 Novartis Ag Methods for the prediction of suicidality during treatment

Also Published As

Publication number Publication date
BRPI0510775A (pt) 2007-11-20
AU2005250142A1 (en) 2005-12-15
MXPA06014127A (es) 2007-01-31
CN1973051A (zh) 2007-05-30
US20090281090A1 (en) 2009-11-12
WO2005118848A1 (en) 2005-12-15
EP1756314A1 (en) 2007-02-28
JP2008505060A (ja) 2008-02-21
CA2568729A1 (en) 2005-12-15
RU2006146207A (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
US7795033B2 (en) Methods to predict the outcome of treatment with antidepressant medication
MX2008016524A (es) Biomarcadores para la progresion de la enfermedad de alzheimer.
US20230386637A1 (en) Polymorphisms for Predicting Treatment Response to Antipsychotic Drugs and Identifying New Drug Targets
US20070065821A1 (en) Methods for the prediction of suicidality during treatment
JP2020089370A (ja) 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法
AU2005250142B2 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US20090118350A1 (en) Biomarkers for Identifying Efficacy of Tegaserod in Patients with Chronic Constipation
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
EP1673472B1 (en) Use of genetic polymorphisms to predict drug-induced hepatotoxicity
US20060183146A1 (en) Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs
KR20070022710A (ko) 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커
WO2016057810A1 (en) Markers for assessing risk of developing or having obsessive compulsive disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired